Engineered immune cells aim to tame childhood autoimmune diseases

NCT ID NCT07490041

Recruiting now Disease control Sponsor: The Children's Hospital of Zhejiang University School of Medicine Source: ClinicalTrials.gov ↗

First seen Apr 01, 2026 · Last updated Apr 30, 2026 · Updated 5 times

Summary

This early-stage study tests a new treatment made from a child's own immune cells, engineered to target and calm overactive immune cells that cause severe rheumatic diseases like lupus. About 36 children aged 5 and older who have not responded to standard treatments will receive a single infusion of these cells. The main goal is to check safety, but researchers will also see if the treatment can bring the disease into remission for up to a year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

The Children's Hospital of Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

CONNECTIVE TISSUE DISEASE-ASSOCIATED INTERSTITIAL LUNG DISEASE PEDIATRIC RHEUMATOLOGICAL CONDITION (I.E., ARTHRITIS, SLE, KAWASAKI'S DISAESE) RHEUMATIC DISEASES SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)